The Nintendo Switch has been revealed, with more to come April 2. Here's what's confirmed and what we're still guessing at.

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. | Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. Months after sharing obesity data that ...

If she goes, she risks not coming back to her family or her beloved island. Here's where Moana 2 really shows us how far Moana has grown. With age and greater status in Motunui, she's become far ...

How might Medicare price negotiations impact Novo Nordisk's battle in the marketplace with Eli Lilly? Lilly's type 2 diabetes drug Mounjaro and obesity drug Zepbound aren't eligible for Medicare ...

Bernard Arnault is once again in charge of Europe's most valuable company. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...

Wegovy was approved as a 2.4mg dose by the US Food and Drug Administration (FDA) in June 2021 and in the EU in January 2022. Novo Nordisk development executive vice-president Martin Holst Lange said: ...

Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial ...

Novo Nordisk is facing serious pressure from a ... patients taking Zepbound lost 20.2% of their weight on average, whereas patients taking Wegovy lost just 13.7% on average. Lilly's drug also ...

This partnership aims to accelerate the development of new treatments for obesity, cardiovascular diseases, and type 2 diabetes. Novo Nordisk saw its stock price increase in both Denmark and the ...

Novo Nordisk (NVO) announced Friday that its popular obesity therapy, semaglutide, marketed as Wegovy, led to 20.7% weight loss over 72 weeks at a higher dose of 7.2 mg in a late-stage trial.